This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

Do BRCA Patients Benefit from ADCs? | This Moment in Medicine

Oncotype or Prosigna — Which Genomic Test Is More Informative? | This Moment in Medicine

Neoadjuvant or Adjuvant T-DXd? | This Moment in Medicine

Navigating ‘Discordant’ Breast Cancer Genomic Assays | This Moment in Medicine

Gedatolisib Triplet Yields Impressive PFS Curves in HR+ mBC | This Moment in Medicine

How the EMERALD Trial & Elacestrant Changed ER-Positive mBC | This Moment in Medicine

This Moment in Medicine | Breast Cancer Updates That Will Change Clinical Practice

Selecting DESTINY-Breast11 vs. Alternative Approaches with Drs. Abi Siva & Carey Anders

Neoadjuvant T-DXd and pCR in DESTINY-Breast11 with Drs. Abi Siva & Carey Anders

DESTINY-Breast05, DESTINY-Breast11 and T-DXd Integration with Drs. Abi Siva & Carey Anders

Managing Early-Stage T-DXd Toxicities with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

First-Line T-DXd in HER2+ mBC with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Adjuvant T-DXd or T-DM1? — with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Managing ILD for Early-Stage T-DXd with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Implementing DESTINY-Breast05 with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

DESTINY-Breast11: Early-Stage HER2+ BC with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Camizestrant Safety & Tolerability with Drs. Anne O'Dea & Mabel Mardones

Delaying Time to Chemotherapy in SERENA-6 with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 Quality of Life Benefits with Drs. Anne O'Dea & Mabel Mardones

ESR1 ctDNA Clearance & Early Response in SERENA-6 with Drs. Anne O'Dea & Mabel Mardones

Understanding ESR1 Resistance with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 & ctDNA Monitoring in Practice with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 & ctDNA-Guided Therapy in mBC with Drs. Anne O'Dea & Mabel Mardones

How ASCENT Changed TNBC Care with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Why PFS2 Matters in mTNBC with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Managing Trop-2 ADC Toxicities with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

TROPION-Breast02 Results with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

ASCENT-03 & ASCENT-04 Results with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Does Crossover Affect OS? with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Evolving ADCs in 1L mTNBC with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Interpreting Overall Survival & PFS in mTNBC ADC Trials with Drs. Sangeetha Reddy & Ahmed Elkhanany

EMERALD-3 Roundtable: Is Multidisciplinary Care the Future of Intermediate-Stage HCC?

EMERALD-3 Roundtable: Low Hepatitis Rates with Durvalumab, Tremelimumab & TACE in HCC

EMERALD-3 Roundtable: Can We Apply TACE + Immunotherapy Data to TARE?

EMERALD-3 Roundtable: Why PFS Matters More Than Ever in Hepatocellular Carcinoma

EMERALD-3 Roundtable: Are HCC Trials Reflecting Real-World Practice?

EMERALD-3 Roundtable: The Role of CTLA-4 in Long-Term HCC Survival

PTEN Loss & AKT Therapy Resistance in HR+/HER2-mBC with Drs. Ursa Brown Glaberman & Karthik Giridhar

Strategies for Successful Capivasertib Management with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Proactive Toxicity Management for Capivasertib with Drs. Ursa Brown-Glaberman & Karthik Giridhar

PI3K/AKT-Directed Second-Line Therapy in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Biomarker Testing in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Maximizing Endocrine Therapy in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar

MATTERHORN Roundtable: Can ctDNA Guide Treatment Decisions in Gastric Cancer?

MATTERHORN Roundtable: What Should We Do After Poor Pathologic Response?

MATTERHORN Roundtable: Does Every Patient Need a Full Year of Adjuvant Durvalumab?

MATTERHORN Roundtable: Real-World Challenges with Adjuvant FLOT

MATTERHORN Roundtable: Does Pathologic Complete Response Predict Survival?

MATTERHORN Roundtable: Does PD-L1 Matter in Curative-Intent Upper GI Cancer?

MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer

HER2+ mBC: First-Line Sequencing and Maintenance with Drs. Rena Callahan & Aditya Bardia

T-DXd in First-Line for HER2+ Metastatic Breast Cancer with Drs. Rena Callahan & Aditya Bardia

Early-Stage T-DXd: CNS Outcomes and ILD Management with Drs. Rena Callahan & Aditya Bardia

Managing Residual Disease After Neoadjuvant T-DXd with Drs. Rena Callahan & Aditya Bardia

Targeting Residual Disease with T-DXd: Patient Selection with Drs. Rena Callahan & Aditya Bardia

Implementing DESTINY-Breast11 & DESTINY-Breast05 in Practice with Drs. Rena Callahan & Aditya Bardia